MEDIGENE AG |
Market Closed -
Other stock markets
|
After market 03:27:58 pm | |||
| 1.72 EUR | -10.42% |
|
1.74 | +1.16% |
Presentation Operator MessageOperator (Operator)Greetings and welcome to Medigene Corporate Ca...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Calendar
2024-04-25
- Europe CHI Immuno- Oncology Summit
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.92
EUR
Average target price
2.675
EUR
Spread / Average Target
+39.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.79% | 50.2M | |
| -0.26% | 103B | |
| +3.61% | 96.73B | |
| +1.66% | 21.31B | |
| -16.22% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.96% | 13.68B | |
| +6.77% | 13.44B | |
| +22.25% | 10.98B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Transcript : Medigene AG - Special Call
